Literature DB >> 26579688

Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy.

Raja Ramachandran1, Vinod Kumar1, Ritambhra Nada2, Vivekanand Jha1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26579688     DOI： 10.1038/ki.2015.310

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  1 in total

1.  Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up.

Authors:  Anne-Els van de Logt; Julia M Hofstra; Jack F M Wetzels
Journal:  Kidney Int       Date:  2015-06       Impact factor: 10.612
  1 in total
  11 in total

Review 1.  Membranous Nephropathy: A Journey From Bench to Bedside.

Authors:  Jean M Francis; Laurence H Beck; David J Salant
Journal:  Am J Kidney Dis       Date:  2016-04-13       Impact factor: 8.860

2.  Immunohistochemical and serological characterization of membranous nephropathy in children and adolescents.

Authors:  Anne K Dettmar; Thorsten Wiech; Markus J Kemper; Armin Soave; Michael Rink; Jun Oh; Rolf A K Stahl; Elion Hoxha
Journal:  Pediatr Nephrol       Date:  2017-10-15       Impact factor: 3.714

Review 3.  A Proposal for a Serology-Based Approach to Membranous Nephropathy.

Authors:  An S De Vriese; Richard J Glassock; Karl A Nath; Sanjeev Sethi; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2016-10-24       Impact factor: 10.121

4.  Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy.

Authors:  Yan-Ni Wang; Hao-Yu Feng; Xin Nie; Ya-Mei Zhang; Liang Zou; Xia Li; Xiao-Yong Yu; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

Review 5.  Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy.

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

6.  Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.

Authors:  Gabriel Stefan; Simona Stancu; Adrian Zugravu; Otilia Popa; Dalia Zubidat; Nicoleta Petre; Gabriel Mircescu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

7.  Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels.

Authors:  Yuemeng Sun; Ping Lan; Jie Feng; Zhigang Wang; Chao Liu; Liyi Xie; Xiaoyang Yu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

8.  Temporal Association Between PLA2R Antibodies and Clinical Outcomes in Primary Membranous Nephropathy.

Authors:  R Ramachandran; A K Yadav; V Kumar; N Inamdar; R Nada; K L Gupta; V Jha
Journal:  Kidney Int Rep       Date:  2017-09-14

9.  Utility of Determining Autoantibodies to M-type Phospholipase A2 Receptor in Diagnosing Primary Membranous Nephropathy: An Ideal Setting.

Authors:  R Ramachandran; V Kumar; N Singh; M Kataruka; V Kumar; M Rathi; H S Kohli; V Jha; K L Gupta
Journal:  Indian J Nephrol       Date:  2017 Sep-Oct

Review 10.  Immune-Monitoring Disease Activity in Primary Membranous Nephropathy.

Authors:  Paolo Cravedi; Marta Jarque; Andrea Angeletti; Àlex Favà; Chiara Cantarelli; Oriol Bestard
Journal:  Front Med (Lausanne)       Date:  2019-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.